| About the author: |
Skrypnyk I.M., Maslova G.S. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The article presents the results of our own studies to assess the frequency and nature of the of of the liver functional disorders development in patients with acute myeloid leukemia, as well as the feasibility of prescribing S-ademethionine against the background of chemotherapy as part of the supportive care. Development of hepatotoxic reactions was recorded on the 7th day of chemotherapy in 32.1% (9/28) of group I patients who received only chemotherapy, and in 4.2% (1/24) of group II patients who were additionally prescribed S-ademethionine. Hepatotoxic reactions during chemotherapy for acute myeloid leukemia in 22.2% (2/9) patients corresponded to the cytolytic type, 44.4% (4/9) to the cholestatic type, and 33.3% (3/9) to the mixed type. On the 28th day of observation, the recurrence of hepatotoxic reactions was recorded. It has been proven that inclusion of S-ademethionine into the treatment of acute myeloid leukemia chemotherapy is associated with a reduced risk of hepatotoxic reactions (RR = 0.13; 95% CI = 0.018-0.95; p<0.05). |
| Tags |
acute myeloid leukemia, chemotherapy, hepatotoxic reactions, S-ademethionine |
| Bibliography |
- Yeremina YeYu. Lekarstvennyye porazheniya pecheni. Gastroenterologiya Sankt-Peterburga. 2012; 1:16-23. [in Russian]
- Ilchenko LYu. Vozmozhnosti primeneniya ademetionina u patsiyentov s nealkogolnoy zhirovoy boleznyu pecheni. Meditsinskiy sovet. 2016;5:150-4. [in Russian]
- Skrypnyk IM, Maslova HS. Otsinka chastoty rozvytku i kharakteru hepatotoksychnykh reaktsiy u khvorykh na hostri miyeloyidni leykemiyi v dynamitsi induktsiyi-remisiyi. Suchasna hastroenterolohiya. 2018; 2:16-22. [in Ukrainian]
- Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch AD, et al. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. J Clin Gastroenterol Hepatol. 2018; 2(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327955/ doi: 10.21767/2575-7733.1000047.
- Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci. 2016 Feb 6; 17(2):224.
- Fey MF, Buske C. ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct; 24 (Suppl 6):vi138-43. doi: 10.1093/annonc/mdt320. Epub 2013 Aug 22.
- Lu SC, Mato JM. S-Adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct; 92(4):1515-42. doi: 10.1152/physrev.00047.2011.
- Pugazhendhi A, Edison TNJI, Velmurugan BK, Jacob JA, Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018 May 1; 200:26-30. doi: 10.1016/j.lfs.2018.03.023. Epub 2018 Mar 10.
- Santini D, Vincenzi B, Massacesi C, Picardi A, Gentilucci UV, Esposito V, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Ress. 2003Nov-Dec; 23(6D):5173-9.
- Tian YM, Dou LP, Yao S, Yao ZL, Zhang QF, Yu L, et al. Protective effect of ademetionine 1,4-butanedisulfonate on liver injury caused by chemotherapeutic agents. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1305-8. doi: 10.7534/j.issn.1009-2137.2013.05.044.
- Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut. 2009; 58:1555-64. doi: 10.1136/gut.2008.163675.
- Vincenzi B, Armento G, Spalato Ceruso M, Catania G, Leakos M, Santini D, et al. Drug-induced hepatotoxicity in cancer patients-implication for treatment. Expert Opin Drug Saf. 2016 Sep; 15(9):1219-38. doi: 10.1080/14740338.2016.1194824. Epub 2016 Jun 14.
- Vincenzi B, Russo A, Terenzio A, Galvano A, Santini D, Vorini F, Antonelli-Incalzi R, et al. The use of SAMe in chemotherapy-induced liver injury. Crit Rev Oncol Hematol. 2018 Oct; 130:70-7. doi: 10.1016/j.critrevonc.2018.06.019. Epub 2018 Jul 31.
- Vincenzi B, Santini D, Maria-Frezza A, Berti P, Vespasiani U, Picardi A, et al. The role of S-adenosylmethionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011 May; 10(3):345-9. doi: 10.1517/14740338.2011.562888. Epub 2011 Mar 15.
|
| Publication of the article |
«World of Medicine and Biology» №4(70), 2019 year, 159-163 pages, index UDK 616.155.392-085 |
| DOI |
10.26724/2079-8334-2019-4-70-159-163 |
